

Fall 11-2-2015

Delivering steady-state product quality with an intensified and integrated perfusion cell culture process

Jason Walther
Sanofi, jason.walther@sanofi.com

Neha Shah
Sanofi

Myles Hollenbach
Sanofi

Jonathan Wang
Sanofi

Marcela Yu
Sanofi

See next page for additional authors

Follow this and additional works at: http://dc.engconfintl.org/biomanufact_ii

 Part of the [Biomedical Engineering and Bioengineering Commons](#)

Recommended Citation

Jason Walther, Neha Shah, Myles Hollenbach, Jonathan Wang, Marcela Yu, Jiuyi Lu, Konstantin Konstantinoc, and Chris Hwang, "Delivering steady-state product quality with an intensified and integrated perfusion cell culture process" in "Integrated Continuous Biomanufacturing II", Chetan Goudar, Amgen Inc. Suzanne Farid, University College London Christopher Hwang, Genzyme-Sanofi Karol Lacki, Novo Nordisk Eds, ECI Symposium Series, (2015). http://dc.engconfintl.org/biomanufact_ii/59

This Conference Proceeding is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Integrated Continuous Biomanufacturing II by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.

Authors

Jason Walther, Neha Shah, Myles Hollenbach, Jonathan Wang, Marcela Yu, Jiuyi Lu, Konstantin Konstantinoc, and Chris Hwang

DELIVERING STEADY-STATE PRODUCT QUALITY WITH AN INTENSIFIED AND INTEGRATED PERFUSION CELL CULTURE PROCESS

Jason Walther, Sanofi
jason.walther@sanofi.com
Neha Shah, Sanofi
Myles Hollenbach, Sanofi
Jonathan Wang, Sanofi
Marcella Yu, Sanofi
Jiuyi Lu, Sanofi
Yang Yang, Sanofi
Agata Villiger-Oberbek, Sanofi
Konstantin Konstantinov, Sanofi
Chris Hwang, Sanofi

Key Words: Perfusion, high cell density, cell-specific perfusion rate, product quality

Continuous biomanufacturing provides many important strategic advantages for the production of protein therapeutics through process integration, simplification and intensification. To achieve upstream process intensification, Sanofi is currently developing robust cell culture processes that can achieve ultra-high cell densities and productivities (“push to high”) while minimizing cell-specific perfusion rates (“push to low”). We have applied ATF perfusion technology and improved the cell culture environment to achieve high cell densities and volumetric productivities with minimal ATF filter fouling. Meanwhile, we have employed high-throughput screening strategies to increase medium depth and reduce medium requirements. We will describe results as well as ongoing efforts to further intensify this continuous cell culture platform and realize even more of its significant upward potential.

Continuous biomanufacturing also has the potential to deliver robust, steady-state product quality, resulting in enormous operational flexibility. Instead of traditionally defining batches by unit operation, product can be batched in time (first-in, first-out), removing downstream processing constraints and minimizing production cycle times. In this presentation, we use both theoretical models and experimental data to evaluate the effects of perfusion on product quality, considering the impact of perfusion-specific controllable parameters (e.g., perfusion rate, bleed rate, target viable cell density) on product quality. We also compare and contrast product quality attributes between perfusion and fed-batch processes and examine the feasibility of maintaining a process and product quality at steady state while presenting relevant, real-world case studies.